Downloads provided by UsageCounts
pmid: 32804789
pmc: PMC7448718
handle: 20.500.12210/40965 , 2123/23340 , 11369/412414 , 11586/314869
pmid: 32804789
pmc: PMC7448718
handle: 20.500.12210/40965 , 2123/23340 , 11369/412414 , 11586/314869
Objectives: There are over 4,000 trials conducted in people with coronavirus disease 2019. However, the variability of outcomes and the omission of patient-centered outcomes may diminish the impact of these trials on decision-making. The aim of this study was to generate a consensus-based, prioritized list of outcomes for coronavirus disease 2019 trials. Design: In an online survey conducted in English, Chinese, Italian, Portuguese, and Spanish languages, adults with coronavirus disease 2019, their family members, health professionals, and the general public rated the importance of outcomes using a 9-point Likert scale (7–9, critical importance) and completed a Best-Worst Scale to estimate relative importance. Participant comments were analyzed thematically. Setting: International. Subjects: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public, and health professionals (including clinicians, policy makers, regulators, funders, and researchers). Interventions: None. Measurements: None. Main Results: In total, 9,289 participants from 111 countries (776 people with coronavirus disease 2019 or family members, 4,882 health professionals, and 3,631 members of the public) completed the survey. The four outcomes of highest priority for all three groups were: mortality, respiratory failure, pneumonia, and organ failure. Lung function, lung scarring, sepsis, shortness of breath, and oxygen level in the blood were common to the top 10 outcomes across all three groups (mean > 7.5, median ≥ 8, and > 70% of respondents rated the outcome as critically important). Patients/family members rated fatigue, anxiety, chest pain, muscle pain, gastrointestinal problems, and cardiovascular disease higher than health professionals. Four themes underpinned prioritization: fear of life-threatening, debilitating, and permanent consequences; addressing knowledge gaps; enabling preparedness and planning; and tolerable or infrequent outcomes. Conclusions: Life-threatening respiratory and other organ outcomes were consistently highly prioritized by all stakeholder groups. Patients/family members gave higher priority to many patient-reported outcomes compared with health professionals.
Male, Outcome Assessment, coronavirus, Critical Care and Intensive Care Medicine, patients, /dk/atira/pure/subjectarea/asjc/2700/2706; name=Critical Care and Intensive Care Medicine, Health Services Accessibility, Health Priorities/organization & administration, sepsis, Outcome Assessment, Health Care, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being, Pandemics/prevention & control, Randomized Controlled Trials as Topic, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Pneumonia, Viral/prevention & control, clinical trial, Middle Aged, COVID-19 (Enfermedad), Clinical trial, covid-19, Research Design, outcome, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, Female, Symptom Assessment, 2706 Critical Care and Intensive Care Medicine, Infection, Coronavirus Infections, Adult, Critical Care, Patients, Pneumonia, Viral, Clinical Investigations, 610, /dk/atira/pure/subjectarea/asjc/2700/2706, 613, clinical trial;coronavirus;critical care;infection;patients;sepsis, Betacoronavirus, Sepsis, Humans, Pandemics, Aged, Randomized Controlled Trials as Topic/standards, Health Priorities, SARS-CoV-2, Viral/prevention & control, COVID-19, Pneumonia, Coronavirus Infections/drug therapy, Health Services Accessibility/standards, infection, name=SDG 3 - Good Health and Well-being, COVID-19 Drug Treatment, Health Care, Coronavirus, critical care, Critical care, name=Critical Care and Intensive Care Medicine, 306, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Male, Outcome Assessment, coronavirus, Critical Care and Intensive Care Medicine, patients, /dk/atira/pure/subjectarea/asjc/2700/2706; name=Critical Care and Intensive Care Medicine, Health Services Accessibility, Health Priorities/organization & administration, sepsis, Outcome Assessment, Health Care, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being, Pandemics/prevention & control, Randomized Controlled Trials as Topic, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Pneumonia, Viral/prevention & control, clinical trial, Middle Aged, COVID-19 (Enfermedad), Clinical trial, covid-19, Research Design, outcome, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, Female, Symptom Assessment, 2706 Critical Care and Intensive Care Medicine, Infection, Coronavirus Infections, Adult, Critical Care, Patients, Pneumonia, Viral, Clinical Investigations, 610, /dk/atira/pure/subjectarea/asjc/2700/2706, 613, clinical trial;coronavirus;critical care;infection;patients;sepsis, Betacoronavirus, Sepsis, Humans, Pandemics, Aged, Randomized Controlled Trials as Topic/standards, Health Priorities, SARS-CoV-2, Viral/prevention & control, COVID-19, Pneumonia, Coronavirus Infections/drug therapy, Health Services Accessibility/standards, infection, name=SDG 3 - Good Health and Well-being, COVID-19 Drug Treatment, Health Care, Coronavirus, critical care, Critical care, name=Critical Care and Intensive Care Medicine, 306, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 11 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
| views | 15 | |
| downloads | 33 |

Views provided by UsageCounts
Downloads provided by UsageCounts